Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies
Autor:
Moreno-Torres, Víctor
; Martín-Iglesias, Daniel
; Vivero, Florencia
; González-Echavarri, Cristina
; García-Moyano, Marta
; Enghelmayer, Juan-Ignacio
; Malfante, Pablo
; Gaser, Adrián
; Ruiz-Irastorza, Guillermo
Fecha:
2023Palabra clave:
Revista / editorial:
Seminars in Arthritis and RheumatismCitación:
Moreno-Torres, V., Martín-Iglesias, D., Vivero, F., González-Echavarri, C., García-Moyano, M., Enghelmayer, J. I., ... & EPIMAR cohort Investigators. (2023, January). Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies. In Seminars in Arthritis and Rheumatism (p. 152164). WB Saunders.Tipo de Ítem:
Articulo Revista IndexadaResumen:
Objective: To compare the efficacy, toxicity and glucocorticoid (GC)-sparing effects of intravenous cyclophosphamide (iv CYC) with other immunosuppressive regimes as the induction treatment for Idiopathic Inflammatory Myopathy-Related Interstitial Lung Disease (IIM-ILD). Methods: Observational comparative study of patients with IIM-ILD from the EPIMAR and Cruces cohorts. The main efficacy outcome was a 6 to 12-month improvement >10% in the forced vital capacity (FVC) from baseline. Results: Overall, 47 patients were included: 22 (47%) in the CYC group and 25 (53%) in the non-CYC group (32% azathioprine, 28% GC alone, 20% mycophenolate, 16% calcineurin-inhibitors and methotrexate and 4% rituximab). 81% patients were female with a mean age of 50.4 years. FVC improvement was achieved by 64% patients in the CYC group vs. 32% in the non-CYC group (p = 0.03). In the logistic regression model, CYC was identified as the only independent predictor of FVC improvement (OR=3.97, 95% CI 1.07–14.75). Patients in the CYC group received more methyl-prednisolone pulses (MP) (59% vs. 28% in the non-CYC group, p = 0.03), less initial GCs doses >30 mg/d (19% vs. 77%, p = 0.001) and lower 6-month average doses of prednisone (11 mg/d vs. 31.1 mg/d, p = 0.001). Conclusion: iv CYC showed better functional outcomes than other immunosuppressants in IIM-ILD. The additional use of MP is likely to potentiate the effects of CYC and allows lowering prednisone doses. Therefore, CYC in combination with MP could be considered as the first line induction therapy in IIM-ILD, without limiting its use to rapidly progressive, life-threatening or refractory disease.
Ficheros en el ítem
Nombre: intravenous_cyclophosphamide_improves_functional_outcome_in interstitia_ lung.pdf
Tamaño: 436.7Kb
Formato: application/pdf
Este ítem aparece en la(s) siguiente(s) colección(es)
Estadísticas de uso
Año |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Vistas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
49 |
79 |
Descargas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
51 |
46 |
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Genetic signature detected in T cell receptors from patients with severe COVID-19
Corpas, Manuel; de Mendoza, Carmen; Moreno-Torres, Víctor; Pintos, Ilduara; Seoane, Pablo; Perkins, James R.; Ranea, Juan A.G.; Fatumo, Segun; Korcsmaros, Tamas; Martín-Villa, José Manuel; Barreiro, Pablo; Corral, Octavio Jorge (iScience, 2023)Characterization of host genetic factors contributing to COVID-19 severity promises advances on drug discovery to fight the disease. Most genetic analyses to date have identified genome-wide significant associations involving ... -
I Congreso Español de Videojuegos 2022
González Calero, Pedro Antonio; Gómez Martín, Marco Antonio; Gómez Martín, Pedro Pablo; Gutiérrez Manjón, Sergio; Gutiérrez Sánchez, Pablo; Peinado, Federico; Sánchez-Ruiz Granados, Antonio; Barbancho, Isabel; Blanco Bueno, Carlos; Botella Nicolás, Ana María; Chover, Miguel; Díaz Álvarez, Josefa; Echeverría, Jorge; Fernández Leiva, Antonio J.; Fernández Ruiz, Marta; Gallego-Durán, Francisco; García Sánchez, Pablo; Gutiérrez Vela, Francisco L; Lara-Cabrera, Raúl; León, Carlos; Moreno, Jorge L.; Lozano Muñoz, Alejandro; Mayor, Jesús; Medina Medina, Nuria; Mejías-Climent, Laura; Mora, Antonio M; Munarriz, Jaime; Patow, Gustavo A.; Sagredo-Olivenza, Ismael; Salinas, María-José; Sanchez I. Peris, Francesc Josep; Sánchez-Ruiz, Antonio A; Shliakhovchuk, Elena; Tejada, Jesus (CEUR Workshop Proceedings, 2022){Resumen no disponible] -
Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study
Moreno-Torres, Víctor; Soriano, Vicente; Calderon-Parra, Jorge; Martinez-Urbistondo, Maria; Treviño, Ana; de San Vicente, Zayrho; de Mendoza, Carmen; Ruiz-Irastorza, Guillermo (Autoimmunity Reviews, 2023)INTRODUCTION: SARS-CoV-2 infection and COVID-19 vaccines might have increased the incidence of giant-cell arteritis (GCA) and the risk of associated stroke in Spain. METHODS: Retrospective nation-wide observational ...